Press Releases

Receive E-mail Alerts
18 April 2019 at 7:00 AM EDT
Summary ToggleProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board
LEIDEN, Netherlands & CAMBRIDGE, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, has nominated Bart Filius , Chief
18 April 2019 at 7:00 AM EDT
Summary ToggleProQR Announces Annual Meeting of Shareholders
LEIDEN, Netherlands and CAMBRIDGE, Mass. , April 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the Annual General
15 April 2019 at 7:00 AM EDT
Summary ToggleProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10
LEIDEN, The Netherlands and CAMBRIDGE, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient
1 April 2019 at 7:00 AM EDT
Summary ToggleProQR to Present at the H.C. Wainwright Global Life Sciences Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass. , April 01, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that management will
26 March 2019 at 4:01 PM EDT
Summary ToggleProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 26, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the strategic spin out
11 March 2019 at 4:00 AM EDT
Summary ToggleProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed
5 March 2019 at 7:00 AM EST
Summary ToggleProQR to Present at Cowen Health Care Conference
LEIDEN, Netherlands and CAMBRIDGE, Mass. , March 05, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the management will
27 February 2019 at 7:00 AM EST
Summary ToggleProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
LEIDEN, The Netherlands & CAMBRIDGE, Mass. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today reported its financial results
29 January 2019 at 8:30 AM EST
Summary ToggleProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
LEIDEN, the Netherlands & CAMBRIDGE, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines, today announced its “ProQR Vision 2023” strategy, which is focused on the development and
7 January 2019 at 7:00 AM EST
Summary ToggleProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it has reached
3 January 2019 at 7:00 AM EST
Summary ToggleProQR to Host R&D Day in New York on January 29
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) will host a Research & Development Day for investors on Tuesday, January 29 at 8:00 am ET at the Lotte New York Palace Hotel in New York, NY .
2 January 2019 at 7:00 AM EST
Summary ToggleProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
LEIDEN, Netherlands & CAMBRIDGE, Mass. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that it received Fast Track